![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Quanterix Corporation | NASDAQ:QTRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.21 | 1.62% | 13.21 | 12.91 | 13.54 | 13.26 | 12.65 | 13.00 | 667,894 | 01:00:00 |
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference. Toloue will speak alongside Chief Financial Officer Vandana Sriram in a fireside chat presentation on Wednesday, June 12, 2024, at 2:40 p.m. EST. The session will be made available to attendees and the general public via webcast.
Webcast Information
To access the live webcast of Quanterix’s fireside chat presentation at the conference, please visit this link.
Replays of the presentation will be available for a limited period following the conference. The presentation will also be made available through the Investor Relations section of the company’s website.
To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix’s Simoa® technology, visit www.quanterix.com/simoa-technology.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605682576/en/
Media Contact: PAN Communications Maya Nimnicht 510-334-6273 quanterix@pancomm.com
Investor Relations Contact: Quanterix Francis Pruell (508)-789-1725 ir@quanterix.com
1 Year Quanterix Chart |
1 Month Quanterix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions